EXPERIENCE OF DARBEPORETIN ALFA USE IN MANAGEMENT OF ANAEMIA IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY


Cite item

Full Text

Abstract

Aim Estimation of efficacy of darbepoeitin-alfa in correction of anemia in patients with chronic kidney disease (CKD) on program heamodialysis (HD), previously treated with short-acting recombinant human erythropoeitins (rHuEpo).
Methods 49 patients with CKD stage V on HD (26 male and 23 female, mean age 51,56±14,86 years) were included into the study. All patients were transfered from short-acting rHuEpo to darbepoeitin-alfa.
Results. Treatment with darbepoeitin-alfa was associated with achievement and stabilization of target levels of haemoglobin. (10,3+1,24 g/l after 4 minths of treatment). Darbepoeitin-alfa was well tolerated; it's efficacy was influenced by secondary hyperparathyreoidism.
Conclusion. Darbepoeitin-alfa is effective in achivement and maintenance of target haemoglobin level in heamodialysis patients.

References

  1. Шило В.Ю. Новый эритропоэз - стимулирующий препарат Аранесп (дарбэпоэтин альфа) в коррекции анемии почечного генеза. Нефрология и диализ. 2007; 9(3): 20-25.
  2. Carrera F., Macdougall I. Hemoglobin targets: the jury is still out. Clin. Nephrol. 2008; 69: 8-9.
  3. Carrera F., Disney A., Molina M. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Nephrol. Dial. Transplant. 2007; 22(Suppl. 4): 19-30.
  4. Eschbach J., Egrie J., Downing M. et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N. Engl. J. Med. 1987; 316: 73-78.
  5. KDOQI; National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for anaemia in chronic kidney disease. Am. J. Kidney Dis. 2006; 47: 11-145.
  6. Mix T., Brenner R., Cooper M. et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am. Heart J. 2005; 149: 408-413.
  7. Rutkowski B., Bitterova Z., Ferenczi S. et al. Effectiveness of converting from intravenous (iv) or subcutaneous (sc) recombinant human erythropoietin (rHuEPO) to iv darbepoetin alfa (DA) in end stage renal disease (ESRD) patients (Pts) on hemodialysis (HD) [abstract]. Presented at 218 American Society of Nephrology Annual Congress- 2006- San Diego, CA, USA -TH-PO380.
  8. Molina M., Garcia Hernandez M., Navarro M. et al. Change of EPO treatment from subcutaneous epoetin to intravenous epoetin or darbepoetin alfa. Nefrologia 2004; 24: 564-571.
  9. Rao M., Pereira B. Optimal anemia management reduces cardiovascular morbidity,mortality, and costs in chronic kidney disease. Kidney Int. 2005; 68: 1432-1438.
  10. Faulds D., Sorkin E. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs 1989; 38: 863-899.
  11. Fisher J. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. 2003; 228(1); 1-14.
  12. Foley R., Parfrey P., Harnett J. et al. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am. J. Kidney Dis. 1996; 28: 53-61.
  13. Phrommintikul A., Haas S., Elsik M. et al. Mortality and target haemoglobin concentrations in anaemia patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388.
  14. Singh A., Szczech L., Tang K. et al. Correction of anaemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006; 335: 2085-2098.
  15. Szczech L., Barnhart H., Inrig J. et al. Secondary analysis of the CHOIR trial epoetin-α dose and achieved haemoglobin outcomes. Kidney Int. 2008; 74: 791-798.
  16. Regidor D., Kopple J., Lovesdy C. et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J. Am. Soc. Nephrol. 2006; 17: 1181-1191.
  17. Locatelli F., Aljama P., Barany P. et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant. 2004; 19: 1-47.
  18. Locatelli F., Pisoni R., Combe C. et al. Anaemia in haemodialysis patients of five European countries: association with morbidity andmortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. 2004; 19: 121-132.
  19. Tolman C., Richarson D., Bartlett C. et al. Structured Conversion from Thrice Weekly to Weekly Erythropoietic Regimens Using a Computerized Decision Support System: A Randomized Clinical Study. J. Am. Soc. Nephrol. 2005; 16: 1463-1470.
  20. Biggar P., Ketteler M., Hennemann H. et al. Switch of ESA therapy from darbepoetin-α to epoetin-β in hemodialysis patients: a single-center experience. Clin. Nephrol. 2008; 68: 185-192.
  21. Vanrenterghem Y., Barany P., Mann J.F. et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patient. Kidney Int. 2002; 62: 2167-2175.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies